Captrust Financial Advisors Immunovant, Inc. Transaction History

Captrust Financial Advisors

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$31.31 - $44.19 $337,897 - $476,898	10,792 New	10,792 $454,000
Q1 2022 May 16, 2022	SELL	$5.06 - $8.77 $2,884 - $4,998	-570 Reduced 85.07%	100 $1,000
Q4 2021 Feb 14, 2022	BUY	$7.33 - $9.32 $4,911 - $6,244	670 New	670 $6,000
Q3 2021 Nov 16, 2021	SELL	$7.01 - $11.37 $2,460 - $3,990	-351 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$9.4 - $16.85 $3,299 - $5,914	351 New	351 $4,000

211

66.9M

2.3M

631K

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

Stay updated on Captrust Financial Advisors with notifications on news.